Hartford Investment Management Co. Has $37 Million Stock Position in Eli Lilly and Company $LLY

Hartford Investment Management Co. lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.3% during the second quarter, Holdings Channel reports. The firm owned 47,459 shares of the company’s stock after selling 620 shares during the period. Eli Lilly and Company accounts for about 1.2% of Hartford Investment Management Co.’s portfolio, making the stock its 12th largest position. Hartford Investment Management Co.’s holdings in Eli Lilly and Company were worth $36,996,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. WestEnd Advisors LLC increased its holdings in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter worth approximately $27,000. Citizens National Bank Trust Department grew its holdings in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $40,000. Finally, Mascagni Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $43,000. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock worth $2,894,841 in the last ninety days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $713.87 on Friday. The firm has a market capitalization of $675.65 billion, a PE ratio of 46.66, a PEG ratio of 1.03 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The business’s 50 day moving average is $735.09 and its 200-day moving average is $767.88.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analyst Weigh In

LLY has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Guggenheim lowered their price target on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $939.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.